Evidence map›Paper›PMID 27475095›Full record

ArticleImmunologic research2017

Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?

Antonio Maria Alfano, Alessandra Romito, Cristiana Marchese, Marco Battistini, Giliola Crotti, Arturo Ferrini, Cristina Mancinetti, Tilde Manetta, Giulio Mengozzi, Paola Merlach and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. [Is autoimmune cholangitis-anti-mitochondrial antibody-negative primary biliary cholangitis still an independent disease?]Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Antonio Maria AlfanoClinical Pathology, Hospital ASL TO4, Via Battitore 2, 10073, Ciriè, TO, Italy. antonioalfano@libero.it.
Alessandra RomitoAnalysis Laboratory, Hospital Maria Vittoria ASL TO2, Turin, Italy.
Cristiana MarcheseAnalysis Laboratory, A.O. Ordine Mauriziano, Turin, Italy.
Marco BattistiniClinical Pathology, Hospital ASL TO4, Via Battitore 2, 10073, Ciriè, TO, Italy.
Giliola CrottiClinical Pathology, Hospital ASL TO4, Via Battitore 2, 10073, Ciriè, TO, Italy.
Arturo FerriniClinical Pathology, Hospital ASL TO4, Via Battitore 2, 10073, Ciriè, TO, Italy.
Cristina MancinettiClinical Pathology, Hospital ASL TO4, Via Battitore 2, 10073, Ciriè, TO, Italy.
Tilde ManettaBiochimical Laboratory, A.O.U. Città Della Salute E Della Scienza, Turin, Italy.
Giulio MengozziBiochimical Laboratory, A.O.U. Città Della Salute E Della Scienza, Turin, Italy.
Paola MerlachClinical Pathology, Hospital ASL TO4, Via Battitore 2, 10073, Ciriè, TO, Italy.
Marco MigliardiAnalysis Laboratory, A.O. Ordine Mauriziano, Turin, Italy.
Maria Teresa TambuzzoClinical Pathology, Hospital ASL TO4, Via Battitore 2, 10073, Ciriè, TO, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the analytical agreement between results obtained from the indirect immunofluorescence methods and from the multiplexed line-blot assay and EliA-M2, to analyze the diagnostic accuracy in a cohort of primary biliary cirrhosis (PBC) patients and in control patients of two different types of tests for anti-M2 and assess whether, with the advent of a quantitative test, the possibility exists to correlate disease activity with the value of AMA. Serum analysis of 67 patients with fluorescence patterns detected on Hep-2 cells suggestive of PBC-related antibodies and three groups of patients (15 PBC, 16 PBC suspect and 48 disease controls) was carried out. All samples were tested by both a qualitative test multiplexed line-blot Autoimmune Liver Disease Profile Euroline and by a quantitative test EliA-M2 IgG. In order to evaluate a possible correlation between the quantitative M2 and disease activity, we divided patients mixed in a further three groups based on the value EliA-M2. For each of these groups were calculated the average values of the main indices of cholestasis. A perfect agreement was shown between the EliA-M2 and the multiplexed line-blot method for AMA detection. All sera of patients with PBC were positive with both tests, with a 100 % sensitivity. Forty-seven of the 48 sera of the control group were negative for both tests with a 100 % next specificity, and only 70 % for the AMA-IIF. We had also observed in the other three groups of patients that the average of the values of γ-glutamyl transpeptidase and alkaline phosphatase increases with the increase of the value EliA-M2. The difference between the mean values of the most significant parameter which the alkaline phosphatase of the three groups is significant, with a statistically significant difference between the first and the third group (p value 0.023). Both the qualitative method Profile Euroline and the quantitative EliA-M2 have a high diagnostic accuracy for PBC, with a specificity higher than the immunofluorescence method. These preliminary data might suggest the possibility of using the dosage EliA-M2 not only in the diagnosis phase but also in the monitoring of disease activity.

Indexed as

AdultAgedAged, 80 and overAutoantibodiesCell Line, TumorFemaleHumansImmunologic TestsLiver Cirrhosis, BiliaryMaleMiddle AgedMitochondriaSensitivity and SpecificityAutoantibodiesAnti-mitochondrial antibodiesAntinuclear PBC-correlated antibodiesIndirect immunofluorescence microscopyPrimary biliary cirrhosisPrognosisSolid phase methods

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.